Dr. Jhaveri on Results of Taselisib in PIK3CA-Mutated Metastatic Solid Tumors

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a basket study of taselisib in patients with PIK3CA-mutated solid tumors.

The safety and efficacy of taselisib, an oral, potent, selective inhibitor of class I PI3Kα, γ, and δ isoforms, was presented during the 2018 AACR Annual Meeting. This open-label phase I study enrolled patients with PIK3CA-mutated tumors who had progressed after, or failed to respond to at least 1 prior therapy.

Findings showed that taselisib has preliminary clinical activity in this patient population with an acceptable safety profile. While higher activity was seen with the 6 mg dose, that dose was not as well tolerated as the 4 mg dose, as it had more toxicities, Jhaveri says. Serious adverse events were observed in 68 patients (46.6%), with the most common being colitis (5.5%) and diarrhea (4.1%).